Post-Gilead-Kite Cancer-Deal Boom? Cool Your Hopes - Bloomberg
We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt | Nasdaq
Puma Biotech to pay PPD founder $22M in defamation suit from proxy fight | Fierce Pharma
Puma pounces on failed Takeda drug, snapping up cancer prospect
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Why Puma Biotech Could Get Acquired Between July to September of This Year | BioSpace
/cloudfront-us-east-2.images.arcpublishing.com/reuters/VE4SVIOXA5KJLBYGVH2UMAY3SY.jpg "Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters")
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
FDA panel backs Puma's neratinib, clearing path to approval | Fierce Biotech
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Takeda farms out cancer drug alisertib to Puma Biotech -
UBS Has Nine Biotech Buyout and Merger Candidates – 24/7 Wall St.
Puma Shares Soar 81% Over 2 Days - Los Angeles Business Journal
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology: Alisertib Deal Alters My Strategy (NASDAQ:PBYI) | Seeking Alpha
Takeda farms out cancer drug alisertib to Puma Biotech -
For Hedge Funds, a Year of Highs and Lows - WSJ
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today | The Motley Fool
Puma Biotechnology Announces $10 Million Private Placement
Why Puma Biotechnology Is Soaring Today | The Motley Fool
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
2016 Biotech Stock Prediction: It's Going to Be a Bummer Year, Folks - TheStreet
